Clinical Trial Update: The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing whether adalimumab affects cardiovascular and metabolic risk in patients with psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Psoriasis
• Type 2 Diabetes Mellitus

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Medical University of Vienna | Conditions: Psoriasis, Cardiovascular Diseases | Phase 4 | Status: UNKNOWN